Zoghbi Huda Y 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Jan 4, 2024
Insider Transaction Report
Form 4
Zoghbi Huda Y
Director
Transactions
- Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2024-01-02−1,117→ 0 totalExercise: $391.92Exp: 2026-09-09→ Common Stock (1,117 underlying) - Award
Non-Qualified Stock Option (right to buy)
2024-01-02+1,607→ 1,607 totalExercise: $888.34Exp: 2034-01-02→ Common Stock (1,607 underlying) - Exercise/Conversion
Common Stock
2024-01-02$391.92/sh+1,117$437,775→ 2,364 total - Award
Common Stock
2024-01-02+135→ 1,382 total - Sale
Common Stock
2024-01-02$900.00/sh−1,117$1,005,300→ 1,247 total
Footnotes (4)
- [F1]Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 5, 2023.
- [F2]Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
- [F3]The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
- [F4]On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.